Artigos

Search for articles

BJO Oncology - Placeholder

Targeted Therapy in a Rare Spindle Cell Tumor with Gene Fusion Rearrangement: A Case Report ETV6-NTRK3

Abstract Introduction Advances in genomic tools have significantly improved the classification of soft tissue tumors (STTs), enabling the identification of specific subsets characterized by recurrent fusions and genetic alterations involving the Raf-1 proto-oncogene, serine/threonine kinase (RAF1), B-Raf proto-oncogene, serine/threonine kinase (BRAF), and neurotrophic tyrosine receptor kinase (NTRK) genes. The present...
BJO Oncology - Placeholder

Outcome of Immunotherapy in Advanced Cervical Cancer after Progression to Platinum-Based Therapy in the Real World

Abstract Introduction Cervical cancer remains a global health concern, particularly in low- and middle-income countries. Immunotherapy has demonstrated meaningful improvements in the overall survival (OS) of patients with recurrent, persistent, or metastatic disease that progressed to platinum-containing chemotherapy. The present study aimed to evaluate real-world outcomes with the use of immunotherapy...
BJO Oncology - Placeholder

Uterine carcinosarcoma with microsatellite instability - does immunotherapy modify the therapeutic scenario? A case report and literature review

ABSTRACT Carcinosarcomas were reclassified by World Health Organization as high-grade uterine carcinomas in 2014. Due to its rare histology, comprising only 5% of uterine carcinomas, there is a small representation of this tumor in studies that evaluate metastatic uterine carcinomas treatment. In 2022, the treatment of metastatic uterine carcinomas has...
BJO Oncology - Placeholder

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil

ABSTRACT To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March 2021 and comprised 20 medical oncologists focus on gynecological oncology. The panel answered...